Kairos Pharma (NYSEAMERICAN:KAPA) Given Buy Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Kairos Pharma (NYSEAMERICAN:KAPA) in a research note released on Thursday morning,Benzinga reports. The firm currently has a $9.00 price target on the stock.

KAPA has been the subject of a number of other reports. Maxim Group initiated coverage on shares of Kairos Pharma in a report on Thursday, March 27th. They set a “buy” rating and a $4.00 price objective for the company. HC Wainwright assumed coverage on Kairos Pharma in a report on Thursday, April 3rd. They set a “buy” rating and a $12.00 price objective for the company.

Kairos Pharma Trading Up 5.8 %

Shares of NYSEAMERICAN KAPA opened at $0.96 on Thursday. Kairos Pharma has a 12 month low of $0.85 and a 12 month high of $4.00. The stock has a 50 day simple moving average of $1.11.

About Kairos Pharma

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.